Louis Manzo - Mar 31, 2022 Form 4 Insider Report for CAPRICOR THERAPEUTICS, INC. (CAPR)

Role
Director
Signature
/s/ Linda Marban, Attorney-in-Fact
Stock symbol
CAPR
Transactions as of
Mar 31, 2022
Transactions value $
-$3
Form type
4
Date filed
4/1/2022, 05:00 PM
Previous filing
Jan 4, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAPR Common Stock Options Exercise $38.8K +27.9K $1.39 27.9K Mar 31, 2022 Direct
transaction CAPR Common Stock Tax liability -$38.8K -11.3K -40.53% $3.43 16.6K Mar 31, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -15.5K -100% $0.00* 0 Mar 31, 2022 Common Stock 15.5K $1.39 Direct F2, F3
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -12.4K -100% $0.00* 0 Mar 31, 2022 Common Stock 12.4K $1.39 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on March 31, 2022 of $3.43. The options would otherwise expire on April 27, 2022, pursuant to their terms.
F2 This option was granted on April 27, 2012 and was previously reported as covering 154,555 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F3 The shares vested 1/48th of the first day of each month, commencing May 1, 2012.
F4 This option was granted on April 27, 2012 and was previously reported as covering 124,491 shares at an exercise price of $0.37 per share, but was adjusted to reflect a 1-for-10 reverse stock split that occurred on June 4, 2019 and a share reprice to $1.39 per share that occurred on February 12, 2020.
F5 The shares vested immediately.